<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695432</url>
  </required_header>
  <id_info>
    <org_study_id>Vaccine2016</org_study_id>
    <nct_id>NCT03695432</nct_id>
  </id_info>
  <brief_title>Probiotic and Influenza Vaccination to Reducing Influenza-like Illness Incident in Elderly</brief_title>
  <official_title>Role of Probiotic and Influenza Vaccination on Immune Response Enchancement and Influenza-Like Illness Incidence Reduction in Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <brief_summary>
    <textblock>
      To asses the effect of the probiotic and influenza vaccination alone and combination on
      enhancing immune response to influenza-like illness (ILI) and reducing ILI incidence in the
      elderly
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To see percetange of subjects seroconvertion and seroprotection before and after intervention
      in the elderly (&gt;60 years), and monitored for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The precentage enhancement of the immune response to flubio vaccine and probiotic compared to plasebo 6 months after vaccination</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with anti HI titer &gt;=1:40</measure>
    <time_frame>6 months</time_frame>
    <description>Describe seroprotection on 4-weeks, 4-months, and 6-months after interventions in elderly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage subjects with increasing antibody titer &gt;=4 times</measure>
    <time_frame>6 months</time_frame>
    <description>Describe seroconvertion on 4-weeks, 4-months, and 6-months after interventions in elderly</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">910</enrollment>
  <condition>Influenza-like Illness</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo probiotic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>capsul</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flubio</intervention_name>
    <description>Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lacidofil</intervention_name>
    <description>Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Vaccine</intervention_name>
    <description>Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly</description>
    <arm_group_label>Placebo Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo probiotic</intervention_name>
    <description>Capsul</description>
    <arm_group_label>Placebo probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all health elderly aged ≥ 60 years

          -  who came to the vaccination and health education activities in the entire East Jakarta
             District Health Center

          -  with Body Mass Index (BMI) 17,5-29,9

          -  healthy mental status (MMSE score of 28-30)

        Exclusion Criteria:

          -  subject who have contraindications to influenza vaccinations

          -  are undergoing treatment related to immune system modulation in the past 4 weeks

          -  therapy for immunossuppresants and/ or corticosteroids eqivalent to prednisone ≥ 20
             mg/day that is being lived more than 2 weeks or has only been stopped less than 3
             months before the study

          -  recieved influenza vaccination less than one year before

          -  Currently consuming probiotic agents, either in the form of a manufacturer or natural
             for more than 7 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sukamto Koesnoe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Allergic and Imunologic, Department of Internal Medicine, Indonesia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Integrated Health Post, at Pulo Gadung District</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>13310</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>October 3, 2018</last_update_submitted>
  <last_update_submitted_qc>October 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Sukamto Koesnoe</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Influenza-like Illness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

